(—)-Deprenyl Combined with L-Dopa in the Treatment of Parkinson’s Disease

  • T. S. Elizan
Part of the Milestones in Drug Therapy book series (MDT)


The fundamental cause of idiopathic Parkinson’s disease (PD) has remained unknown since its original description in the 19th century. Despite this fact, a rational therapeutic approach (exogenous replacement of the missing neurotransmitter, dopamine) was successfully introduced by Cotzias in 1967 [1], following the conceptual framework of Carlsson in 1959 [2], who suggested that dopamine may be a transmitter in the central nervous system involved in the control of motor function and may be involved in the parkinsonian syndrome; and the impressive neurochemical data of Hornykiewicz in 1963 [3] which definitively demonstrated a significant reduction in nigrostriatal dopamine concentration in both idiopathic and postencephalitic Parkinson’s disease. Since then, the major therapeutic efforts have been primarily focused on modifications of the “delivery” of L-dopa [4–8], the use of dopamine agonists [9–12], and, more recently, the use of monoamine oxidase inhibitors, either alone or as adjuvants to levodopa therapy [13–18]. The latter therapeutic approach (specifically the use of a selective MAO-B inhibitor, selegiline (l-deprenyl) in combination with levodopa) is the focus of this review.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of Parkinsonism. N Engl J Med 1967; 276: 374–379.CrossRefGoogle Scholar
  2. [2]
    Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 1959; 11: 490–493.Google Scholar
  3. [3]
    Hornykiewicz O. Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-hydroxytryptamin) in der substantia nigra des normalen und parkinsonkranken Menschen. Wien Klin Wschr 1963; 75: 309–312.Google Scholar
  4. [4]
    Yahr MD, Duvoisin RC, Mendoza MR, Senear MJ, Barrett RE. Modification of L-dopa therapy of parkinsonism by alpha-methyl-dopa hydrazine (MK-486). Trans Am Neurol Asso 1971; 96: 55–58.Google Scholar
  5. [5]
    Eckstein B, Shaw K, Stern G. Sustained release levodopa in parkinsonism. Lancet 1973; i: 431–432.CrossRefGoogle Scholar
  6. [6]
    Hardie RJ. LeesAJ, Stern GM. On-off fluctuations in Parkinson’s disease. A clinical and neuropharmacological study. Brain 1984; 107: 487–506.CrossRefGoogle Scholar
  7. [7]
    Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson’s disease: pathogenetic and therapeutic studies. Ann Neurol 1987; 22: 475–479.CrossRefGoogle Scholar
  8. [8]
    Cederbaum JM, Breck L, Kutt H, McDowell FH. Controlled-release levodopa/car-bidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson’s disease. Neurology 1987; 37: 233–241.CrossRefGoogle Scholar
  9. [9]
    Olanow CW, Alberts M J. Double-blind controlled study of pergolide mesylate in the treatment of Parkinson’s disease. Clin Pharmacol 1987; 10: 178–185.Google Scholar
  10. [10]
    Libman I, Gawd M J, Riopelle RJ, Bouchard S. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of “de novo” Parkinson’s disease patients. Can J Neurol Sci 1987; 14: 576–580.Google Scholar
  11. [11]
    Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: A 5-year follow-up. Neurology 1987; 37: 826–828.CrossRefGoogle Scholar
  12. [12]
    Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurology 1989; 39: 336–339.CrossRefGoogle Scholar
  13. [13]
    Birkmayer W, Riederer P, Youdim MBH, Linauer W. The potentiation of the anti-akinetic effect after L-dopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975; 36: 303–326.CrossRefGoogle Scholar
  14. [14]
    Riederer P, Przuntek H. MAO-B inhibitor selegiline (R-(-)-deprenyl): a new therapeutic concept in the treatment of Parkinson’s disease. J Neural Transm 1987; [Supplement] 25: 1–197.Google Scholar
  15. [15]
    The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364–1371.CrossRefGoogle Scholar
  16. [16]
    Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA, Selegiline use to prevent progression of Parkinson’s disease. Experience in 22 de novo patients. Arch Neurol 1989; 46: 1275–1279.CrossRefGoogle Scholar
  17. [17]
    Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA. Selegiline as an adjunct to conventional levodopa therapy in Parkinson’s disease. Experience with this type B monoamine oxidase inhibitor in 200 patients. Arch Neurol 1989; 46: 1280–1283.CrossRefGoogle Scholar
  18. [18]
    Elizan TS, Moros DA, Yahr MD. Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson’s disease: Experience in 26 patients receiving combined therapy for 26 months. Arch Neurol 1991; 48: 31–34.CrossRefGoogle Scholar
  19. [19]
    Cotzias GC, Papavasilou PS, Gellene R. Modifications of parkinsonism-chronic treatment with L-dopa. New Engl J Med 1969; 280: 337–345.CrossRefGoogle Scholar
  20. [20]
    Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969; 21: 343–354.CrossRefGoogle Scholar
  21. [21]
    Marsden CD, Parkes JD. Success and problems of chronic levodopa therapy in Parkinson’s disease. Lancet 1977; i: 345–349.CrossRefGoogle Scholar
  22. [22]
    Yahr MD. Evaluation of long-term therapy in Parkinson’s disease: mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O, editors. Advances in Parkinsonism. Basel: Roche, 1976; pp. 435–444.Google Scholar
  23. [23]
    Yahr MD. Overview of present day treatment of Parkinson’s disease. J Neural Transm 1978; 43: 227–238.CrossRefGoogle Scholar
  24. [24]
    Yahr MD. Limitations of long-term use of anto-parkinson drugs. Can J Neurol Sci 1984; 2: 191–194.Google Scholar
  25. [25]
    Zeller AA, Barsky V. In vivo inhibition of liver and brain monoamine oxidase by l-isonicotinyl-2-isopropylhydrazine. Proc Soc Exp Biol Med 1952; 81: 459.CrossRefGoogle Scholar
  26. [26]
    Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin im Gehirn des Menschen und ihr Verhalten Bei Erkrankungen des extrapyramidalen Systems. Wien Klin Wschr 1960; 72: 1236.CrossRefGoogle Scholar
  27. [27]
    Bernheimer V, Birkmayer W, Hornykiewicz O. Verhalten der Monoaminooxydase im Gehrin des Menschen Nach Therapie mit Monoaminooxydase-Hemmern. Wien Klin Wschr 1962; 74: 558–559.Google Scholar
  28. [28]
    Barbeau A, Duchastel Y. Tranylcypromine and the extrapyramidal syndrome. Can J Psychiat 1962; 7: 91–95.Google Scholar
  29. [29]
    Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet 1963; ii: 849–851.CrossRefGoogle Scholar
  30. [30]
    Horwitz D, Lorenberg W, Engelman K, Sjoerdsma A. Monoamine oxidase inhibitors, tyramine and cheese. JAMA 1964; 188: 1108–1110.CrossRefGoogle Scholar
  31. [31]
    Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968; 17: 1285–1297.CrossRefGoogle Scholar
  32. [32]
    Knoll J, Ecsery Z, Kelemen, K, Nievel J, Knoll B. Phenylisopropyl-methylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 1965; 155: 154.Google Scholar
  33. [33]
    Knoll J. Magyar K. Some puzzling effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972; 5: 393–408.Google Scholar
  34. [34]
    Youdim MBH, Collins GGS, Sandler M, Pare CMB, Bervan Jones AB, Nicolson WJ. Human brain monoamine oxidase: multiple forms and selective inhibition. Nature 1972; 236: 225–228.CrossRefGoogle Scholar
  35. [35]
    Glover V, Sandler M, Owen R, Riley GV. Dopamine is a monoamine oxidase-B substrate in Man. Nature 1977; 265: 80–81.CrossRefGoogle Scholar
  36. [36]
    Sandler M, Glover V, Ashford A, Stern GM. Absence of “cheese effect” during deprenyl therapy: some recent studies. J Neural Transm 1978; 43: 209–215.CrossRefGoogle Scholar
  37. [37]
    Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacology 1978; 57: 33–38.CrossRefGoogle Scholar
  38. [38]
    Knoll J. The possible mechanisms of action of (—)-deprenyl in Parkinson’s disease. J Neural Transm 1978; 43: 177–198.CrossRefGoogle Scholar
  39. [39]
    Knoll J. Extension of life span of rats by long-term (—)-deprenyl treatment. Mt Sinai J Med 1988; 55: 67–74.Google Scholar
  40. [40]
    Lees A, Shaw KM, Kohent LJ, Stern GM, Elsworth JD, Sandler M, Youdim MBH. Deprenyl in Parkinson’s disease. Lancet 1977; ii: 791–796.CrossRefGoogle Scholar
  41. [41]
    Rinne UK, Siirtola T, Sonninen V. l-Deprenyl treatment of on-off phenomena in Parkinson’s disease. J Neural Transm 1978; 43: 253–262.CrossRefGoogle Scholar
  42. [42]
    Stern GM, Lees AJ, Sandler M, Recent observations on the clinical pharmacology of deprenyl. J Neural Transm 1978; 43: 245–251.CrossRefGoogle Scholar
  43. [43]
    Schacter M, Marsden CD, Parkes JD, Jenner P, Testa B. Deprenyl in the management of response fluctuations in patients with Parkinson’s disease on levodopa. J Neurol Neurosurg Psychiat 1980; 43: 1016–1021.CrossRefGoogle Scholar
  44. [44]
    Birkmayer W, Knoll J, Riederer P, Youdim MBH. (-)-Deprenyl leads to prolongation of L-dopa efficiency in Parkinson’s disease. Med Probl Pharmacopsychiat 1983; 19: 170–176.Google Scholar
  45. [45]
    Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Morton J. Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson’s disease: a long-term study. J Neural Transm 1985; 64: 113–127.CrossRefGoogle Scholar
  46. [46]
    Heikkila RE, Manzino L, Duvoisin RC, Cabbat FS. Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidase inhibitors. Nature 1984; 311: 467–469.CrossRefGoogle Scholar
  47. [47]
    Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD. Pargyline and deprenyl prevent the neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 1984; 106: 209–210.CrossRefGoogle Scholar
  48. [48]
    Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA. l-Deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson’s disease: experience in 200 patients. Adv Neurol 1990; 53: 431–435.Google Scholar
  49. [49]
    Fischer PA, Baas H. Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism. J Neural Transm 1987; [Supplement] 25: 137–147.Google Scholar
  50. [50]
    Poewe W, Gerstenbrand F, Ransomayr G. Experience with selegiline in the treatment of Parkinson’s disease. J Neural Transm 1987; [Supplement] 25: 131–135.Google Scholar
  51. [51]
    Cohen G. Monoamine oxidase, hydrogen peroxide, and Parkinson’s disease. Adv Neurol 1986; 45: 119–125.Google Scholar
  52. [52]
    Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson’s disease. Proc Natl Acad Sci USA 1989; 86: 1398–1400.CrossRefGoogle Scholar
  53. [53]
    Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989; 28: 689–690.CrossRefGoogle Scholar
  54. [54]
    Hauser AR, Olanow CW. Early therapy for Parkinson’s disease (letter to the editor). Arch Neurol 1991; 48: 1009.CrossRefGoogle Scholar
  55. [55]
    Hefti F, Melamed E, Bhawan J, Wurtman RI. Long-term administration of L-dopa does not damage dopaminergic neurons in the mouse. Neurology 1981; 31: 1194–1195.CrossRefGoogle Scholar
  56. [56]
    Melamed E. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson’s disease. Mt Sinai J Med 1988; 55: 35–42.Google Scholar
  57. [57]
    Brannan T, Martinez-Tica J, Yahr M. Effect of long-term L-dopa administration on striatal extracellular dopamine release. Neurology 1991; 45: 596–598.CrossRefGoogle Scholar

Copyright information

© Springer Basel AG 1993

Authors and Affiliations

  • T. S. Elizan

There are no affiliations available

Personalised recommendations